Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Actinium Pharmaceuticals (ATNM) Payables (2021 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Payables for 8 consecutive years, with $7.2 million as the latest value for Q4 2025.

  • Quarterly Payables changed N/A to $7.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $7.2 million through Dec 2025, changed N/A year-over-year, with the annual reading at $7.2 million for FY2025, N/A changed from the prior year.
  • Payables for Q4 2025 was $7.2 million at Actinium Pharmaceuticals, up from $6.2 million in the prior quarter.
  • The five-year high for Payables was $15.9 million in Q4 2023, with the low at $3.4 million in Q2 2021.
  • Average Payables over 5 years is $7.2 million, with a median of $7.2 million recorded in 2025.
  • The sharpest move saw Payables soared 108.56% in 2022, then fell 15.94% in 2025.
  • Over 5 years, Payables stood at $5.5 million in 2021, then surged by 83.02% to $10.1 million in 2022, then skyrocketed by 57.02% to $15.9 million in 2023, then crashed by 54.77% to $7.2 million in 2024, then grew by 0.72% to $7.2 million in 2025.
  • According to Business Quant data, Payables over the past three periods came in at $7.2 million, $6.2 million, and $7.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.